| Document |
Document Title |
|
JP5006987B2 |
To provide a treatment and prevention medicine containing an ALK (Anaplastic Lymphoma Kinase) blocking compound and useful for disease accompanied by abnormality of ALK such as cancer, cancer metastasis depression or cognitive dysfunctio...
|
|
JP5007428B2 |
A compound of the formula (I) wherein the bond between carbon atoms 22 and 23 indicated with a broken line is a single or double bond, n is 0, 1 or 2, R 1 represents, for instance, a C 1 -C 12 alkyl group, R 2 represents, for instance, R...
|
|
JP5001234B2 |
The use of AIVLOSIN, as such or as a pharmaceutically acceptable (non-toxic) derivative such as an acid addition salt, for the preparation of a veterinary medicament for the treatment and prophylaxis of diseases and infections of pigs an...
|
|
JP4996464B2 |
The invention relates to substituted fluoroglycoside derivatives of pyrazoles of formula (I) as further defined in the specification, to the physiologically compatible salts thereof, to a method for their production, and to their use as ...
|
|
JP4992008B2 |
|
|
JP2012516886A |
The present invention relates to a process for preparing compound of formula (I) that is Cleistanthin A. The process comprises the steps of reacting compound of formula (II) with compound of formula (III) in the presence of a first solve...
|
|
JP4981846B2 |
Antimicrobial compounds having the formula (II) (III) (IV) (IV-A) or (V) as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infec...
|
|
JP4981776B2 |
Antimicrobial compounds having the formula (II) (III) (IV) (IV-A) or (V) as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infec...
|
|
JP4987187B2 |
Water miscible pharmaceutical compositions containing up about 40% of a marcrolide such as an azalide antibiotic are prepared by reaction of the macrolide with acid in a non-aqueous water miscible organic solvent system.
|
|
JP4980217B2 |
A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided.
|
|
JP4981198B2 |
Acyl derivatives of glycosyl-L-ascorbic acids which have a higher oil-solubility than L-ascorbic acid, glycosyl-L-ascorbic acids, and inorganic esters of L-ascorbic acid such as phosphates and sulfates of L-ascorbic acid. When administer...
|
|
JP4975933B2 |
The invention concerns a method for preparing 9-deoxo-8a-aza-(8a-alkyl)-8a-homoerythromycin A and its 8a-alkyl derivatives from 9-deoxo-9(Z)-hydroxyiminoerythromycin A via a Beckmann stereospecific rearrangement in a reaction medium usin...
|
|
JP2012126753A |
To provide compounds and/or compositions that modulate PP2A activity.Certain compounds of the formulae (e.g., formula I, Ia, Ib and the like), and its classes and subclasses modulate the activity of PP2A. Compounds that modulate the acti...
|
|
JP2012121907A |
To provide a glucuronide derivative of tanaproget.A method of generating synthetic metabolites of tanaproget derivatives is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples ...
|
|
JP4950380B2 |
PCT No. PCT/SE98/01287 Sec. 371 Date Aug. 12, 1998 Sec. 102(e) Date Aug. 12, 1998 PCT Filed Jun. 29, 1998 PCT Pub. No. WO99/02542 PCT Pub. Date Jan. 21, 1999A pharmaceutical composition comprising a nucleotide analogue and one or more gl...
|
|
JP2012107075A |
To provide polymorphs of compound Ia that are especially desirable for use in pharmaceutical formulations.This invention relates to the polymorphs of a motilide having a structure represented by formula (Ia).
|
|
JP4939761B2 |
|
|
JP2012097072A |
To provide a pharmaceutical composition composed of the extracts of a plurality of crude drugs, which causes reduced side-effects and has high safety while exhibiting an excellent antibacterial action and has urease inhibitory activity, ...
|
|
JP4936507B2 |
|
|
JP4936234B2 |
The invention relates to a crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]
-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, to a method for the preparation thereof, as well as to the use thereof for p...
|
|
JP2012092109A |
To provide new strategies and protocols for oligosaccharide synthesis.There are provided a method for synthesizing a compound having the structure (I) (wherein R is H) and related oligosaccharides useful as a vaccine for inducing antibod...
|
|
JP4932128B2 |
A glucoside containing isomaltol represented by formula (I): (wherein Sug represents a glucose residue or a sugar linkage composed of two or more glucose units) as an aglycon, a physiologically active substance containing the glucoside h...
|
|
JP2012509885A |
Disclosed herein are processes for preparing glucopyranosyloxypyrazole derivatives and pyrazole intermediates of the same. In particular, the present invention relates to glucopyranosyloxypyrazole derivatives having SGLT2 inhibitory acti...
|
|
JP2012082147A |
To provide a collagen gel-shrinking agent that shrinks collagen gel comprising collagen and a fibroblast, and an AGE production inhibitor and/or a saccharification inhibitor.The collagen gel-shrinking agent uses silybin maltoside represe...
|
|
JP4908213B2 |
Described is a compound of the formula (I) wherein the bond between carbon atoms 22 and 23 is a single or double bond; m is 0 or 1; R1, is C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl; and either (A) R2 is —N(R3)R4, and (1) X is 0, wh...
|
|
JP4910092B2 |
|
|
JP4904621B2 |
The topical application of an azalide antibiotic such as azithromycin and an additional medicament to the eye is useful in treating or preventing ocular infections. In one embodiment, the azalide antibiotic is supplied to the eye in a de...
|
|
JP4902348B2 |
The present invention provides nitrogen-containing fused-ring derivatives represented by the following general formula, or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in ...
|
|
JP4902925B2 |
The invention provides a nucleic acid molecule comprising: (a) a nucleotide sequence as shown in SEQ ID No. 35; or (b) a nucleotide sequence which is the complement of SEQ ID No. 35; or (c) a nucleotide sequence which is degenerate with ...
|
|
JP4902151B2 |
To provide a method for producing a hesperetin-7-β-maltoside and to provide uses thereof. The method for producing the hesperetin-7-β-maltoside is characterized as follows. Hesperidin is reacted with an enzyme having an α-1,6-rhamnosi...
|
|
JP2012505843A |
Administration scheme of an analgesically active polar metabolite of an opioid or the salt thereof for the manufacture of a medicament for the treatment of pain after medical operation, whereas the medicament is administered at least onc...
|
|
JPWO2010038842A1 |
The present application is based on formula (I).(In the formula, the symbol is as described in the specification.) Provided are a compound represented by the above, and a method for producing the compound. The compound has a lipase inhib...
|
|
JP4888840B2 |
The present invention relates to processes for preparing the compounds of general formula I, wherein the groups R1 to R6 and R7a, R7b, R7c are defined according to claim 1. Furthermore the present invention relates to processes for prepa...
|
|
JP2012036146A |
To provide a light-induced retinopathy inhibitor containing a new ingredient as an active ingredient.This invention is characterized as follows: 1. a light-induced retinopathy inhibitor containing an extract from black rice as an active ...
|
|
JP4881004B2 |
A composition for external use, comprising 2-O-(²-D-glucopyranosyl)ascorbic acid represented by the formula (I): or a salt or ester thereof which is safe to the human body, and a koji mold or a processed koji. The composition for extern...
|
|
JP2012031098A |
To provide a novel hepatitis C virus infection inhibitor of an action mechanism which inhibits the growth of virus particles in an uncoating process in a life ring of a hepatitis C virus and/or in an infection post stage, and to treat or...
|
|
JP4873785B2 |
A method for screening a cysteine protease inhibitor of which cysteine protease inhibitory activity is enhanced in the presence of endogenous polyvalent metal ion, which comprises treating a cysteine protease with a test compound in the ...
|
|
JP4869347B2 |
During the investigation of the mechanism that cellular water in woody plants growing in cold districts keeps liquid state at low temperature, the inventors have studied to identify the causative substances. As the results, the present i...
|
|
JP4873904B2 |
Disclosed is an agent for amelioration of impaired ophthalmic arterial blood flow. Also disclosed is a method for amelioration of impaired ophthalmic arterial blood flow. An agent for amelioration of impaired ophthalmic arterial blood fl...
|
|
JP4871467B2 |
The invention relates to spherical telithromycin clusters and to a method for the production thereof characterized in that a telithromycin crystal suspension is prepared, said crystals are coated with a telithromycin insoluble phase whic...
|
|
JPWO2010027108A1 |
The present invention provides a simple, rapid, and highly sensitive method for detecting a sugar-binding protein, and a fluorescent compound necessary for the detection. Specifically, in the present invention, when a sugar-binding prote...
|
|
JP2012021009A |
To provide a composition for preventing and treating a stuffy nose caused by type I allergy and pollinosis related to the type I allergy.There are provided a food composition for preventing a stuffy nose caused by pollinosis contains as ...
|
|
JP4864259B2 |
A use of Icariin in preparing the medicine for preventing and treating sexual disorder and vasoconstrictive diseases.
|
|
JP4864184B2 |
A subject of the invention is a process for the preparation of the compounds of formula (I): Wherein the substituents are defined as in the application. The compounds of this invention exhibit antibiotic properties.
|
|
JP4864302B2 |
|
|
JP4854843B2 |
|
|
JP4856809B2 |
An dermatological agent for external use is disclosed which contains a chromanol glycoside represented by the following general formula (1) (wherein R<1>, R<2>, R<3>, and R<4>, which may be the same or different, each represent a hydroge...
|
|
JP4850302B1 |
The present invention aims to provide a particulate composition containing anhydrous crystalline 2-O- ± -D-glucosyl-L-ascorbic acid having a significantly, hardly solidifiable property compared to conventional ones in a grade for use in...
|
|
JP4851094B2 |
What is described are a compound of the formula wherein n is 0 or 1; A-B is —CH═CH— or —CH2—CH2—; R1 is C1-C12-alkyl, C3-C8-cycloalkyl or C2-C12-alkenyl; R2 is for example C1-C12-alkyl, C2-C12-alkenyl or C2-C12-alkinyl; which...
|
|
JP4846758B2 |
|
